BLAINJECTIONINJECTABLE
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
4/8 — Partial
Xeomin (incobotulinumtoxina) by Merz Therapeutics is acetylcholine release inhibitors [moa]. First approved in 2010.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xeomin (incobotulinumtoxinA) is a botulinum toxin type A injectable that inhibits acetylcholine release at the neuromuscular junction. It is used to treat dynamic wrinkles and muscle hyperactivity conditions through localized paralysis of targeted muscles. The product represents a purified, naked toxin formulation without complexing proteins, distinguishing it from other botulinum competitors.
$3MPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $3M, the brand team is transitioning toward defensive positioning; expect smaller, more specialized commercial teams focused on retention over expansion.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Retrospective Chart Abstraction to Investigate the Prevalence of Chronic Sialorrhea, and the Real-world Use of incobotulinumtoxinA Injections in Male and Female Participants Aged 18 Years and Older With Chronic Sialorrhea
Started Oct 2025
206 enrolled
Sialorrhea
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Started Aug 2025
997 enrolled
Episodic Migraine
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Started Aug 2025
808 enrolled
Chronic Migraine
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
Started Jun 2022
30 enrolled
Spastic Cerebral Palsy
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Started Jul 2021
45 enrolled
Healthy Participants
Worked on Xeomin at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.